ArticleOncogene2026
SEC14L4 promotes the development of esophageal squamous cell cancer by inhibiting the ubiquitination and degradation of DDX3X via RNF39.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Esophageal squamous cell cancer (ESCC) remains an aggressive malignant tumor with limited therapeutic options and poor prognosis. This study aims to uncover novel diagnostic markers and therapeutic targets by investigating molecular drivers of ESCC pathogenesis using integrated omics and functional assays. The gene expression profiles of ESCC tissues were compared with those of normal tissues. SEC14L4 expression was evaluated through qPCR, Western blot, and immunohistochemistry (IHC). Functional roles of SEC14L4 were assessed through cell proliferation, colony formation, apoptosis, migration, and invasion assays. Co-immunoprecipitation (Co-IP) and mass spectrometry were used to discover SEC14L4-interacting proteins. Ubiquitination assays assessed the degradation of DDX3X. The MAPK pathway and ferroptosis markers were analyzed by Western blot to investigate the downstream effects of SEC14L4. In vivo tumor models were used to validate SEC14L4's oncogenic role. SEC14L4 was markedly overexpressed in ESCC tissues, correlating with advanced tumor stage and reduced overall survival. In vitro, SEC14L4 promoted ESCC cell proliferation, migration, and colony formation, while inhibiting apoptosis, while its knockdown reduced these effects. DDX3X overexpression rescued these phenotypes. Co-IP and mass spectrometry confirmed a direct interaction between SEC14L4 and DDX3X, and SEC14L4 was found to inhibit DDX3X ubiquitination via RNF39. SEC14L4 promotes ESCC progression by activating the MAPK signaling pathway and inhibiting ferroptosis. In vivo, SEC14L4 knockdown significantly inhibited tumor growth. SEC14L4 facilitates ESCC development by inhibiting the ubiquitination and degradation of DDX3X by RNF39.
Indexed as
Identifiers
41741625What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.